Board Meeting Decisions
The board meeting commenced at 01:00 PM and concluded at 06:15 PM on 31st October, 2026 at the Registered Office of the Company at Plot 2/5198 ETC, 5th Floor, 5003, World Trade Centre, Near Udhna Darawaja, Ring Road, Surat, 395002.
Key decisions taken:
1. Considered and approved Standalone and Consolidated Unaudited Financial Results along with Limited Review Report, Statement of Deviation and Variation and Certificate of Utilisation of Proceeds of IPO of the company for the half year ended 30th September 2026.
2. Appointment of Ms. Shubhangi Rajesh Gadia as Company Secretary & Compliance Officer of the company effective from 1st November, 2026.
3. Investment in a Proposed Wholly owned Subsidiary company named "VEDANT NUTRITION LIMITED" having a total paid up capital of Rs. 10,00,000/- comprising of 1,00,000 equity shares of Rs. 10/- each.
Updated Key Managerial Personnel
Consequent upon the appointment of Ms. Shubhangi Rajesh Gadia, the updated details of authorised Key Managerial Personnel (KMP) are:
- Hiren Indravadan Desai - Managing Director
- Aayush Hiren Desai - Whole-Time Director
- Sahil Bhaveshkumar Modi - CFO
- Shubhangi Rajesh Gadia - Company Secretary
Contact: Email Id: info@vahhchemicals.com, Telephone No.: 0261-2344045
Standalone Financial Results (Half Year Ended 30th September 2026)
Financial Performance (₹ in Lakhs)
| Particulars | 30-09-2026 | 31-03-2026 | 30-09-2025 | 31-03-2026 |
| Revenue From Operations | 1,947.85 | 2,184.53 | 1,040.11 | 3,224.64 |
| Other Income | 9.85 | 0.03 | 0.00 | 0.03 |
| Total Revenue | 1,957.70 | 2,184.56 | 1,040.11 | 3,224.66 |
| Profit before tax | 360.62 | 342.09 | 199.75 | 541.85 |
| Tax Expenses | 88.26 | 92.16 | 53.93 | 146.09 |
| Profit for the period | 272.37 | 249.94 | 145.82 | 395.76 |
Equity Share Capital
- Paid-up share Capital: ₹830.59 lakh (increased from ₹606.39 lakh)
- Face Value of Equity Share: ₹10
- Earnings per share (Basic, non-annualised): ₹3.46
- Earnings per share (Basic, annualised): ₹6.91
Financial Position (₹ in Lakhs)
| Particulars | 30-09-2026 | 31-03-2026 |
| Share Capital | 830.59 | 606.39 |
| Reserves & Surplus | 2,052.33 | 817.49 |
| Total Shareholders' Funds | 2,882.92 | 1,423.88 |
| Total Assets | 4,392.11 | 3,011.69 |
| Cash and Cash Equivalents | 102.65 | 51.86 |
Consolidated Financial Results (Half Year Ended 30th September 2026)
Financial Performance (₹ in Lakhs)
| Particulars | 30-09-2026 | 31-03-2026 | 30-09-2025 | 31-03-2026 |
| Revenue From Operations | 2,586.21 | 2,662.78 | 1,652.47 | 4,315.25 |
| Profit before tax | 483.81 | 420.29 | 274.48 | 694.76 |
| Profit for the period | 362.08 | 308.50 | 200.37 | 508.87 |
| Profit attributable to minority shareholders | 24.90 | 14.58 | 13.71 | 28.29 |
| Profit after minority interest | 337.18 | 293.91 | 186.66 | 480.58 |
| Earnings per share (Basic, non-annualised): ₹4.28
Segment Reporting
The Group operates in two business segments:
1. Chemicals (Vahh Chemicals Limited)
2. Nutraceuticals (HSHS Nutraceuticals Limited - subsidiary)
Segment-wise Revenue for H1 Sep 2026:
- Chemicals: ₹1,947.85 lakh
- Nutraceuticals: ₹638.36 lakh
IPO Proceeds Utilization
The company undertook an initial public offer of 22,42,000 equity shares having face value of ₹10 each at an issue price of ₹60 per share, aggregating ₹1,345.20 lakh as stated in the Prospectus dated 27 May 2026.
Utilization as of 30th September 2026:
| Objects of the issue | Proposed (₹ lakh) | Utilised to 30-09-2026 | Balance (₹ lakh) |
| Incremental working capital | 583.78 | 582.81 | 0.97 |
| New manufacturing facility, Surat | 192.94 | 0.00 | 192.94 |
| Repayment of loan | 184.35 | 124.19 | 60.16 |
| General corporate purposes | 201.78 | 200.00 | 1.78 |
| Net issue proceeds | 1,162.85 | 907.01 | 255.84 |
| Issue-related expenses | 182.35 | 182.29 | 0.06 |
| Gross issue proceeds | 1,345.20 | 1,089.30 | 255.90 |
The unutilised IPO proceeds amounting to ₹255.90 lakh as at 30 September 2026 are represented by the unutilised drawing balance available in the Company's Cash Credit facility and balances maintained in its bank current accounts.
New Subsidiary Investment
The board approved investment in a proposed wholly owned subsidiary company named "VEDANT NUTRITION LIMITED" with total paid up capital of ₹10,00,000 comprising of 1,00,000 equity shares of ₹10 each. The subsidiary will be engaged in the nutraceuticals business including manufacturing, buying, selling, importing, exporting, distributing and marketing nutraceutical products.
Auditor's Review
MAARS & Associates, Chartered Accountants (Firm Registration No.: 134798W) conducted limited review of both standalone and consolidated financial results and issued an unqualified review report stating that nothing has come to their attention that causes them to believe that the financial results contain any material misstatement.